Piramal Pharma Limited
Piramal Pharma Limited, a prominent player in the global pharmaceutical industry, is headquartered in India and operates extensively across key regions, including North America, Europe, and Asia. Founded in 1988, the company has achieved significant milestones, establishing itself as a leader in both contract development and manufacturing, as well as in the formulation of complex generics. Piramal Pharma's core offerings include a diverse range of pharmaceutical products and services, with a strong emphasis on innovative drug delivery systems and advanced therapies. Their commitment to quality and sustainability sets them apart in a competitive market. With a robust portfolio and a focus on research and development, Piramal Pharma Limited continues to enhance its market position, contributing to healthcare solutions worldwide.
DitchCarbon Score
How does Piramal Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Piramal Pharma Limited's score of 42 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Piramal Pharma Limited's reported carbon emissions
In 2025, Piramal Pharma Limited reported total carbon emissions of approximately 32,279,000 kg CO2e for Scope 1 and about 51,363,000 kg CO2e for Scope 2 (market-based), resulting in a combined total of around 83,642,000 kg CO2e (market-based) for Scope 1 and 2 emissions. In 2024, the company recorded approximately 43,383,000 kg CO2e for Scope 1 and about 62,210,000 kg CO2e for Scope 2, leading to a total of around 105,593,000 kg CO2e for Scope 1 and 2 emissions. In 2023, emissions were significantly higher, with Scope 1 at approximately 55,229,000 kg CO2e, Scope 2 at about 58,077,000 kg CO2e, and Scope 3 emissions reaching approximately 450,639,000 kg CO2e. Piramal Pharma has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2022 as the baseline. This target aligns with the 1.5°C decarbonisation pathway recommended by the Science-Based Targets initiative (SBTi). Additionally, the company has committed to a 25% reduction in absolute Scope 3 emissions, which encompass emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, and the use of sold products, also by FY2030. The company’s emissions data is self-reported and does not appear to be cascaded from a parent organisation. Piramal Pharma Limited is actively working towards its climate goals, demonstrating a commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Scope 1 | 41,396,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,243,220 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 477,407,000 | - | 000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Piramal Pharma Limited is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
